Table 1. Demographic information for samples included in gene expression analysis.

Group	Hippocampus (cohort 1)			Orbitofrontal cortex (replication cohort)
	SCZ	BPD	Controls	SCZ	BPD	MDD	Controls
Number	35	33	32	13	14	15	15
Age	42.6	45.4C	43.9	44.65	41.9	46.5	48.1
Age range	19–59	19–64	31–60	25–62	25–61	30–65	29–68
Sex	9F, 26M	18F, 15M	9F, 24M	8M, 5F	9M, 5F	9M, 6F	9M, 6F
Race	34C, 1H	32C, 1NA	32C	10C, 3A	13C, 1AA	15C	14C, 1AA
PMI (h)	31.4	38	30	35.8	30.9	27.5	23.7
PMI range	9–80	12–84	9–58	12–61	13–62	7–47	8–42
pH	6.5	6.4	6.6	6.2	6.2	6.2	6.3
pH range	5.9–6.9	5.8–7	6–7	5.8–6.6	5.8–6.5	5.8–6.5	5.8–6.6
Side	17L, 18R	18L, 15R	15L, 17R	8L, 5R	6L, 8R	9L, 6R	8L, 7R
Mood stabilizers	10Y, 24N	21Y, 11N, 1NA	32N	3Y, 10N	9Y, 5N	2Y, 13N	15N
Antidepressants	9Y, 25N	19Y, 13N, 1NA	32N	5Y, 8N	7Y, 7N	127, 3N	15N
Antipsychotics	35Y	22Y, 11N	32N	12Y, 1N	11Y, 3N	15N	15N
Lifetime dosage	85 004	9915	0	61 077	20 032	0	0
Dosage range	50–400 000	0–130 000	0	0–150 000	0–60 000	0	0

Abbreviations: BPD, bipolar disorder; F, female; L, left; M, male; MDD, major depressive disorder; NA, not available; PMI, postmortem interval; R, right; SCZ, schizophrenia.

Information on matched traits for hippocampus samples (N=100 after removing outliers) from the Stanley Microarray Collection and OFC samples (N=57 after removing outliers) from the Stanley Neuropathology Consortium Collection that were included in the differential expression analysis. 'AA' represents African American, 'A' represents Asian, 'C' represents Caucasian, 'H' represents Hispanic. ‘Mood Stabilizers', ‘Antidepressants' and ‘Antipsychotics' are listed as 'Y' if there is a record of an individual having ever taken one and 'N' if there is no such record. ‘Lifetime dosage' is the mean estimated lifetime dosage of antipsychotics in fluphenazine equivalents (mg). ‘Dosage range' is the lowest and highest lifetime dosages of antipsychotics of all individuals in each group.